This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Strensiq
  • /
  • Safety and Efficacy of Asfotase Alfa in Juvenile P...
Clinical trial

Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)

Read time: 1 mins
Last updated:1st Sep 2009

This clinical trial studied the safety and efficacy of asfotase alfa in children with HPP compared to a historical control group.


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Children With Hypophosphatasia (HPP)
Enrollment: 13
Study Start Date: September 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)

Arms:
- Active Comparator:
2 mg/kg
- Active Comparator: 3 mg/kg

Category Value
Study start date 2009-09-01

View full details